Objective:To investigate the effect of the control quality detection method and common problems of the non-invasive blood pressure. We analyzed the function and characteristics of two kinds of non-invasive blood pressure quality tester to improve quality control testing technology. Methods:We are use theFLUKEBP Pump2 noninvasive blood pressure quality detector of US and Olico BP-SiM noninvasive blood pressure testing instrument to test. We analyzed the results of test. Results:The regular quality control can effectively improve the reliability and reduce the failure rate of the non invasive blood pressure monitor. Conclusion:We are Use the two kinds of non-invasive blood pressure quality testing to ensure the quality and safety of multi-parameter monitor. We are monitor the unqualified for clinical through regular inspection, as the same as, we can ensure the accuracy of clinical diagnosis and the life safety of patients.

Objective:To study the clinical value and telomerase activity of malignant ascites treated by lifein combination with cisplatin.Methods:48 patients with malignant ascites were divided randomly into two groups.Treatment group of 28 cases were treated with lifein and cisplatin,control group of 20 cases were treated with cisplatin alone.Telomerase activity was detected by semi-TRAP assay before treatment,at the first week,the second week and the third week after treatment,respectively.Results:the effective rates of treatment group(89.3%) was much higher than that of control group (60%),P

Objective: To compare the clinical efficacy and safety of bortezomib, cyclophosphamide, dexamethasone (VCD) regimen and bortezomib dexamethasone (VD) regimen in the treatment of the patients with newly diagnosed multiple myeloma (NDMM). Methods: The clinical data of 73 patients with NDMM in Shanxi Dayi Hospital from January 2013 to January 2016 were retrospectively analyzed. According to the chemotherapy regimen, the patients were divided into VCD group (41 cases) and VD group (32 cases). The efficacy and adverse reactions of the two groups were evaluated. Results: The overall response rate of VCD group and VD group was 80.5% (33/41) and 78.1% (25/32) respectively, and the difference was not statistically significant (χ ²= 0.061, P= 0.804); and complete remission (CR) rate was 36.6% (15/41) and 15.6% (5/32) respectively, and the difference was statistically significant (χ ²= 3.970, P= 0.046); the median progression-free survival (PFS) was 27 months and 24 months respectively, and the median overall survival (OS) was 35 months and 33 months respectively, and the differences were not statistically significant (all P > 0.05). Most adverse reactions occurred in grade 1-2, in which peripheral polyneuropathy and thrombocytopenia were the most common. Peripheral neuritis was the most common finding among the adverse reactions of grade 3. The incidence of adverse reactions in both groups was not statistically significant (P > 0.05). Conclusions VCD and VD regimen could be recommended as a better induction therapy for NDMM patients. Compared with VD scheme, VCD scheme has a higher CR rate.